New Therapies for Atopic Dermatitis Crowd the Pipeline


Atopic dermatitis, commonly known as eczema, affects at least 10% of adults in the industrialized world. In recent years, research has broadened our understanding of the underlying mechanisms that drive the condition, leading to identification of potential targets and development of new therapies.

Dr Mark Lebwohl, chairman of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City, explains that the March 2017 approval of dupilumab for moderate to severe atopic dermatitis touched off a new era of systemic treatments. Dozens of new drugs are being investigated, many with promising trial results, giving hope to the millions of patients who suffer from the persistent itch that defines the skin condition.

In this ReCAP, Dr Lebwohl summarizes current knowledge of the pathogenesis of atopic dermatitis and highlights the most promising new therapies in the works.


Professor and Chairman, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.

Mark G. Lebwohl, MD, has disclosed the following relevant financial information:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Allergan; Almirall; Arcutis Biotherapeutics; Avotres Therapeutics; BirchBioMed Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Cara Therapeutics; Castle Biosciences; Corrona; Dermavant Sciences; Evelo Biosciences; Foundation for Research and Education in Dermatology; Inozyme Pharma; Leo Pharma; Meiji Seika Pharma Co.; Menlo Dermatology Medical Group; Mitsubishi Tanabe Pharma America; NeuroDerm; Pfizer Inc.; Promius Pharma LLC; Dr. Reddy's Laboratories; Theravance Biopharma, Inc.; Verrica Pharmaceuticals Inc. ¬

Received research grant from: AbbVie; Amgen Inc.; Arcutis Biotherapeutics; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Celgene Corporation; CLINUVEL; Eli Lilly and Company; Incyte Corporation; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Kadmon Corporation; Leo Pharma; MedImmune Inc.; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Pfizer Inc.; SCIderm; UCB, Inc.; Vidac Pharma.

Next Article: